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Objectives. Basal cell carcinomas (BCCs) are malignant tumors which rarely 
metastasize, are slow-growing, and extensively locally destructive. BCCs 
more than 5 cm in diameter are defined as giant. Most often they arise as a 
result of neglect, as the patient avoids, delays, or refuses to see a doctor. The 
large tumor diameter and consequently of the post-excisional defect make 
these lesions difficult to treat surgically with respect to selecting the surgical 
reconstruction technique. Method. We studied a group of 9 patients, aged 60 
to 85 years, diagnosed with giant basal cell carcinomas (GBCCs) with 
periocular location in which surgery was indicated. Results. In all cases, 
complete excision with histologically clear margins was performed and for 
the coverage of the remaining defect various, complex, and sometimes two-
stage reconstructive techniques were used. Conclusions. Giant cell 
carcinoma of the periocular region requires extensive and risky surgery, 
especially when performed on the elderly. Early referral to a doctor avoids 
all these risks, in all cases the pathological diagnosis was nodular BCCs. The 
aesthetic and functional outcomes were good to very good, and the patients 
reported being highly satisfied.   
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Although it represents only a small percentage of the 
body surface area, approximately 5 to 10 percent of all skin 
cancers occur in the periocular region [1]. Basal cell 
carcinomas (BCCs) account for 90% of malignant eyelid 
tumors, being the most common type of skin cancer in 
Europe, Africa, and North America [2]. BCCs are most 
commonly located on areas with prolonged exposure to 
solar ultraviolet radiation, which is the main risk factor, 
and confirmation of BCCs diagnosis is a negative 
prognostic factor for the development of other associated 
skin lesions [3]. Usually, these malignant tumors are slow-
growing, rarely metastasize, but have a significant local 
destructive potential [4]. However, BCCs may present a 
rare but aggressive biological variant, named giant basal 
cell carcinomas (GBCCs) defined as BCCs with a diameter 
of 5 cm or more characterized by deep tissue invasion, 
rapid growth and high risk of metastasis, increased rate of 
local complications, and poor prognosis [5,6]. GBCCs 
account for 0.4%-1% of all BCCs [7]. The pathogenesis of 
GBCCs is sometimes linked to a spontaneous mutation in 
the human patch gene (PTCH), mapped to the q22.33 locus 
of chromosome 9; however, over 30% of GBCCs cases are 
due to the delay in seeking medical attention, most often 
associated to mental deficiency, low socioeconomic status, 
poor hygiene, advanced age, or the fact that BCCs are 
painless [8]. Although mortality is low, the morbidity 
caused by this tumor is significant due to its locally 
invasive and relapse potential [9,10]. The metastatic 
potential of BCCs is estimated to be less than 0.03%, while 
GBCCs have a higher rate of metastasis [11]. It is reported 
that systemic metastases predominantly occur in giant 
GBCCs exceeding 100 cm2 in surface area or 25 cm in 
diameter [12]. Surgical excision is highly effective, being 
the preferred treatment option over time. BCCs should be 
excised with 3-4 mm safety margins from the adjacent 
macroscopically healthy tissue to exclude microscopic 
invasion of neoplastic cells. Recurrences at the operative 
site, especially periorbital, perinasal, and periauricular, 
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should be treated with great caution; thus, re-excision 
should be carried out early as it has been found that a high 
number of BCCs relapse to become much more aggressive 
[13]. The current study includes a group of 9 patients with 
nodular BCCsover 5 cm in diameter and different 
periocular locations. In all cases, excision with adequate 
margins was performed. Given the large size of the tumors 
as well as of the soft-tissue defects after tumor excision, 
different reconstruction techniques were used, most often 
of great complexity, in some cases even two-stage. 
Materials and Methods 
The current study includes a group of 9 patients, 8 men 
and one woman, aged 60 to 85 years, who presented to the 
Clinic of Plastic Surgery and Reconstructive Microsurgery, 
St. Spiridon Emergency Hospital Iasi, between January 
2017 and July 2018. All patients presented on admission 
ulcerative lesions, bleeding in 3 cases in the periocular 
region. In 4 cases the tumor masses were located at the 
external angle of the right eye, in 2 cases on the lower 
eyelid, in 2 cases at the external angle of the left eye, and 
in one case in the glabellar region with extension to the 
inner angles of both eyes (Figure1). These lesions ranged 
from 5 to 7.5 cm in diameter, which defines them as 
"giant", and were present for 5 to 12 years.  
 
Figure 1. (A) the external angle of the right eye. (B) the 
glabellar region with extension to the inner angles of 
both eyes. (C) the lower eyelid. 
Physical examination on admission made a 
presumptive diagnosis of ulcerated GBCCs carcinoma 
based on the macroscopic appearance, location, and size of 
the lesions, highly suggestive for this type of neoplasm, as 
well as on case history that revealed slow growth over a 
long period of time. Patients were informed about the 
procedures to be undergone and informed consent was 
obtained from all study patients. Preoperative imaging 
explorations consisted of computer tomography (CT) 
examination to determine the degree of tumor invasion of 
the eyeball and its appendages. In all cases, tumor invasion 
of the eyeball was absent, the reason why the indication for 
exenteration was excluded with the agreement and in 
collaboration with the eye surgeon. In all cases, surgery 
was performed under general anesthesia with endotracheal 
intubation and consisted of the surgical removal of the 
masses with adequate surgical margins (Figure 2). 
 
Figure 2. (A) surgical removal of the tumoral 
masses with adequate surgical margins with bone 
extension, including periocular fat. (B) wide 
excision of the giant cell carcinoma of the glabellar 
region. (C) wide excision of the giant cell 
carcinoma of the lower eyelid.  
As all patients were aged over 60, the preoperative 
preparation was done in collaboration with the cardiologist 
and anesthesiologist. Coverage of post-excisional soft-
tissue defects required complex and varied reconstruction 
techniques. Three of the cases required two-stage 
reconstruction. The Mustard-type flap, the forehead and 
genian flap techniques (Fricke flap in one case), and 
advancement genian flap, of which one anchored to the 
zygomatic bone, were used in 3 cases each. In three cases, 
eyeball protection required its coverage with a conjunctival 
flap that was sectioned three months postoperatively, and 
the eyes reopened (Figure 3). 
 
Figure 3. (A)  Mustarde- flap. (B)  the coverage of 
the tissue defect with Mustarde flap. (C) eyeball 
protection with a conjunctival flapwith eye closed.  
(D) association between forhead and genian flap. 
(E) coverage of the soft tissue postexcisional defect 
with a Mustarde flap. 
Results 
The immediate postoperative course was favorable in 
all study cases. In only one case did we find distal venous 
congestion of the flap with a necrotic zone. To cover the 
lower eyelid soft tissue defect resulting from necrectomy, 
a split-thickness skin graft was performed 14 days after 
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surgery. The postoperative edema, ecchymoses, and 
erythema disappeared completely after 4-6 weeks, and the 
end result (functional and esthetic) was assessed 
approximately 3 - 6 months postoperatively (Figure 4). 
 
Figure 4. A,B,C,D,E: functional and aesthetic good 
results in all cases. 
The diagnosis of certainty was made by the 
histopathological examination which revealed in all 
casesand ulcerated nodular BCCs (Figure 5). 
 
Figure 5. (A) Nodular basal cell carcinoma ulcerated 
with fibrin-leukocyte exudate on the surface. Tumor cell 
nests with microcystic dilatations, associating reduced 
desmoplasticstroma (x5 H&E staining). (B) Nodular 
basal cell carcinoma tumor islands of various dimensions, 
having artefactual cleavage space with adjacent tumor 
stroma (x10 H&E staining). (C) Nodular basal cell 
carcinoma with tumor nodules of different sizes and 
shapes. Area of ulceration on the surface with fibrin-
leukocyte debris (x5 H&E staining). 
The indication for adjuvant radio-chemotherapy was 
subsequently established by the oncologist. In all cases 
the excision was performed with histologically clear 
margins (safety margins), re-excision not being needed 
in any of these cases. 
Long-term course was good, with complete flap re-
integration and healing of donor area, without pathological 
scars. The results were assessed from a functional point of 
view (eyelids), color, and texture of flaps, as well as the 
appearance and esthetic impact of the scars, taking into 
account the degree of patient satisfaction. All patients were 
satisfied with the functional as well as the esthetic 
outcomes, with no eyelid occlusion disturbances that could 
possibly affect the visual function. No less important was 
the psychological improvement and the rapid social 
reintegration of these patients, although most of them were 
retired. The histopathological examinations confirmed the 
excision of the masses within the oncological limits in all 
the plans, and clinically no recurrences were found 18 
months postoperatively. 
Discussions 
GBCCs are rarely reported in the literature, being a rare 
oncologic entity. In the TNM classification, they are 
designated T3 [14]. In a study of 17 cases diagnosed with 
GBCCs, Maimaiti et al. reported an 11/6 male 
predominance, while another study by Shuo Fang et al. 
from the Plastic and Reconstructive Surgery Clinic of 
Shanghai Hospital, China showed a 9/6 male 
predominance. In our study, we found a higher male 
predominance, namely 8/1. In the literature, no concrete 
causes for this higher incidence in men are reported. It is 
believed that a possible explanation may be the 
involvement of men in jobs with prolonged exposure to 
ultra violet radiation, associated with a possible higher 
degree of neglect or alcohol consumption. Mean age at the 
time of GBCCs diagnosis is about 67 years [15,16]. In our 
study group the mean age was 72.2 years.  
The socio-economic status of the patients is considered 
to be a major risk factor. As all the patients included in this 
study resided in rural areas, living in precarious conditions 
and having difficulties in accessing healthcare could be 
considered factors that may have contributed to their late 
presentation (after 5 to 12 years) to a specialist, findings 
supported by other reports in the literature [8]. Old age is 
another important risk factor demonstrated by the current 
study, the youngest patient in our study group being aged 
60 and the oldest 85 [9].  Given the patients’ age, possible 
mental deficiencies should not be excluded. All 9 patients 
included in this study reported that they did not experience 
pain throughout tumor development. However, Randle et 
al. reported that GBCCs have a greater propensity to 
metastasize, especially when they reach critical dimensions 
of over 10 cm, and Archontaki et al.found a 17.6% 
incidence of metastases at the time of presentation based 
on the review of the published literature until that time (30 
articles, 51 patients); fortunately, in our study group no 
metastases were identified at the time of presentation or 
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during postoperative follow-up [6, 14]. GBCCs show a 
predilection for lymph node metastasis, but also possible is 
the hematogenous spread with metastases to the 
parenchymal internal organs or bone metastases, which 
causes anemia by replacement of the hematopoietic 
marrow or secondary amyloidosis of the kidney, spleen, or 
intestines, which would considerably worsen the prognosis 
[17-19]. 
Key to successful treatment of periocular GBCCs 
appears to be radical surgical excision, even if it requires 
the removal of important eyelid anatomic elements and 
causes large soft-tissue defects that require laborious 
reconstruction methods [20]. In most small BCCs, the 2-
4mm safety margins provide adequate excision, but 
GBCCs have a higher incidence of subclinical extension 
requiring excisions with 3-5mm safety margins. The 
periocular area is of major functional and esthetic 
importance, which is why it requires special attention, 
especially when it comes to the defects post-excision of a 
GCBCs, where direct suture would give unsatisfactory 
results due to the resulting tension on ocular adnexa [21]. 
The methods for the reconstruction of post-excisional 
defects in the periocular area require the knowledge and 
respect of some principles related to the use of flaps and 
skin grafts that offer safer and more efficient solutions, the 
flaps being preferred over the grafts in this anatomical 
region because their homogeneity in color and texture will 
lead to a better esthetic, functional, and morphological 
unification with the surrounding tissues. In addition, free 
skin plasty cannot be used when the excision reveals 
slightly vascularized anatomical elements, blood vessels, 
or nerves [22]. Often, negative pressure therapy cannot be 
used to obtained a real granular bed for split skin grafting. 
In order to use negative pressure therapy, we must have the 
certainty of a complete excision of the tumor [23]. Loco-
regional flaps had been used for the reconstruction of 
defects in all 9 study patients, the obtained being reported 
above. 
Radiation therapy may have an adjuvant or palliative 
role in GBCCs, especially in patients with extensive facial 
lesions or altered general conditions that would not tolerate 
such an extensive surgery, but the response to this type of 
treatment is heterogeneous and difficult to predict. There 
appears to be no correlation between tumor location and 
the type of response to radiation therapy, but the nodular 
subtype of BCCs is considered to respond well to radiation 
therapy, and the sclerosing BCCs is described as having a 
high recurrence rate after radiation therapy [18, 24]. It 
should be mentioned there is high operative risk for these 
patients who are often elderly and in which no other form 
of local anesthesia can be used [25]. The localization of 
these large tumors of the face is a real challenge in 
choosing the surgical technique, being much more difficult 
than in other anatomical regions of the body [26, 27]. 
Vismodegib is a new treatment option, the only 
medication approved by the US Food and Drug 
Administration in 2012 for the treatment of locally 
advanced or metastatic BCCs. In 54% of the patients 
receiving Vismodegib treatment, the absence of residual 
disease in control biopsies was confirmed. The average 
duration of treatment is 7.6 months, and the common side 
effects are muscle spasms, dysgeusia, alopecia, and weight 
loss. This therapeutic option may be a good alternative in 
patients with contraindications for surgery or metastases 
[28]. 
Conclusions 
Early detection of BCCs and radical surgical treatment 
are probably the most effective weapon against the 
development of a GBCCs. This could be achieved by 
improving the primary health care services and 
encouraging patients to undergo surgery at earlier stages of 
the disease, as well as educating them with regard to the 
course of this disease. Regarding the surgical treatment of 
periocular GBCCs, tumor resection should be done with 
safety margins. Reconstruction of post-excisional defects 
can be performed with local flaps, which is a safe method 
that provides good functional and esthetic outcomes, as 
confirmed by the results of this study. Absence of tumor 
invasion in the resection margins must be confirmed by 
histopathological examination. Given the high relapse rate, 
a long-term follow-up of these patients is required.  
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